keyword
MENU ▼
Read by QxMD icon Read
search

Cognitive impairment biomarkers

keyword
https://www.readbyqxmd.com/read/28319241/alzheimer-disease-signature-neurodegeneration-and-apoe-genotype-in-mild-cognitive-impairment-with-suspected-non-alzheimer-disease-pathophysiology
#1
Stefanie Schreiber, Frank Schreiber, Samuel N Lockhart, Andy Horng, Alexandre Bejanin, Susan M Landau, William J Jagust
Importance: There are conflicting results claiming that Alzheimer disease signature neurodegeneration may be more, less, or similarly advanced in individuals with β-amyloid peptide (Aβ)-negative (Aβ-) suspected non-Alzheimer disease pathophysiology (SNAP) than in Aβ-positive (Aβ+) counterparts. Objective: To examine patterns of neurodegeneration in individuals with SNAP compared with their Aβ+ counterparts. Design, Setting, and Participants: A longitudinal cohort study was conducted among individuals with mild cognitive impairment (MCI) and cognitively normal individuals receiving care at Alzheimer's Disease Neuroimaging Initiative sites in the United States and Canada for a mean follow-up period of 30...
March 20, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28317650/clinical-validity-of-increased-cortical-uptake-of-amyloid-ligands-on-pet-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#2
REVIEW
Konstantinos Chiotis, Laure Saint-Aubert, Marina Boccardi, Anton Gietl, Agnese Picco, Andrea Varrone, Valentina Garibotto, Karl Herholz, Flavio Nobili, Agneta Nordberg
The use of biomarkers has been proposed for diagnosing Alzheimer's disease in recent criteria, but some biomarkers have not been sufficiently investigated to justify their routine clinical use. Here, we evaluate in a literature review the clinical validity of amyloid positron emission tomography (PET) imaging using a structured framework developed for the assessment of oncological biomarkers. Homogenous criteria have been addressed in reviews of other Alzheimer's disease biomarkers. There is adequate evidence that the main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317649/clinical-validity-of-cerebrospinal-fluid-a%C3%AE-42-tau-and-phospho-tau-as-biomarkers-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#3
REVIEW
Niklas Mattsson, Anders Lönneborg, Marina Boccardi, Kaj Blennow, Oskar Hansson
Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317647/clinical-validity-of-medial-temporal-atrophy-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#4
REVIEW
Mara Ten Kate, Frederik Barkhof, Marina Boccardi, Pieter Jelle Visser, Clifford R Jack, Karl-Olof Lovblad, Giovanni B Frisoni, Philip Scheltens
Research criteria for Alzheimer's disease recommend the use of biomarkers for diagnosis, but whether biomarkers improve the diagnosis in clinical routine has not been systematically assessed. The aim is to evaluate the evidence for use of medial temporal lobe atrophy (MTA) as a biomarker for Alzheimer's disease at the mild cognitive impairment stage in routine clinical practice, with an adapted version of the 5-phase oncology framework for biomarker development. A literature review on visual assessment of MTA and hippocampal volumetry was conducted with other biomarkers addressed in parallel reviews...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317646/clinical-validity-of-delayed-recall-tests-as-a-gateway-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#5
REVIEW
Chiara Cerami, Bruno Dubois, Marina Boccardi, Andreas U Monsch, Jean Francois Demonet, Stefano F Cappa
Although Alzheimer's disease criteria promote the use of biomarkers, their maturity in clinical routine still needs to be assessed. In the light of the oncology framework, we conducted a literature review on measures used to assess delayed recall impairment due to medial temporal lobe dysfunction (i.e., free and cued word list recall tests). Ample evidence is available for phases 1 (rationale for use), 2 (discriminative ability), and 3 (early detection ability) for many of the tests in routine use. Evidence about phase 4 (performance in real world) and phase 5 (quantify impact and costs) is yet to come...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317645/the-biomarker-based-diagnosis-of-alzheimer-s-disease-2-lessons-from-oncology
#6
REVIEW
Marina Boccardi, Valentina Gallo, Yutaka Yasui, Paolo Vineis, Alessandro Padovani, Urs Mosimann, Panteleimon Giannakopoulos, Gabriel Gold, Bruno Dubois, Clifford R Jack, Bengt Winblad, Giovanni B Frisoni, Emiliano Albanese
Biomarkers for the diagnosis of Alzheimer's disease (AD) are not yet validated for use in clinical settings. We aim to provide a methodological framework for their systematic validation, by reference to that developed for oncology biomarkers. As for this discipline, the steps for the systematic validation of AD biomarkers need to target analytical validity, clinical validity, and clinical utility. However, the premises are different from oncology: the nature of disease (neurodegeneration vs. cancer), the purpose (improve diagnosis in clinically affected vs...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317644/the-biomarker-based-diagnosis-of-alzheimer-s-disease-1-ethical-and-societal-issues
#7
REVIEW
Corinna Porteri, Emiliano Albanese, Charles Scerri, Maria C Carrillo, Heather M Snyder, Birgitta Martensson, Mark Baker, Ezio Giacobini, Marina Boccardi, Bengt Winblad, Giovanni B Frisoni, Samia Hurst
There is great interest in the use of biomarkers to assist in the timely identification of Alzheimer's disease (AD) in individuals with mild symptoms. However, the inclusion of AD biomarkers in clinical criteria poses socioethical challenges. The Geneva Task Force for the Roadmap of Alzheimer's Biomarkers was established to deliver a systematic strategic research agenda (aka roadmap) to promote efficient and effective validation of AD biomarkers and to foster their uptake in clinical practice. In this article, we summarize the workshop discussion of the Geneva Task Force "ethical and societal issues" working group, which comprised bioethicists, clinicians, health economists, and representatives of those affected by AD...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28314375/inter-subject-variability-of-axonal-injury-in-diffuse-traumatic-brain-injury
#8
Jeffrey B Ware, Tessa Hart, John Whyte, Amanda Rabinowitz, John A Detre, Junghoon Kim
Traumatic brain injury (TBI) is a leading cause of cognitive morbidity worldwide, for which reliable biomarkers are needed. Diffusion tensor imaging (DTI) is a promising biomarker of traumatic axonal injury (TAI), however existing studies have been limited by a primary reliance upon group-level analytic methods not well-suited to account for inter-subject variability. In this study, 42 adults with TBI of at least moderate severity were examined 3 months following injury and compared to 35 healthy controls. DTI data was used for both traditional group-level comparison as well as subject-specific analysis using the distribution-corrected Z-score (DisCo-Z) approach...
March 17, 2017: Journal of Neurotrauma
https://www.readbyqxmd.com/read/28314160/difference-in-imaging-biomarkers-of-neurodegeneration-between-early-and-late-onset-amnestic-alzheimer-s-disease
#9
Anne-Laure Aziz, Bernard Giusiano, Sven Joubert, Lauréline Duprat, Mira Didic, Claude Gueriot, Lejla Koric, José Boucraut, Olivier Felician, Jean-Philippe Ranjeva, Eric Guedj, Mathieu Ceccaldi
Neuroimaging biomarkers differ between patients with early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD). Whether these changes reflect cognitive heterogeneity or differences in disease severity is still unknown. This study aimed at investigating changes in neuroimaging biomarkers, according to the age of onset of the disease, in mild amnestic Alzheimer's disease patients with positive amyloid biomarkers in cerebrospinal fluid. Both patient groups were impaired on tasks assessing verbal and visual recognition memory...
February 21, 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28302757/alteration-of-monoamine-receptor-activity-and-glucose-metabolism-in-paediatric-patients-with-anticonvulsant-induced-cognitive-impairment
#10
Yuankai Zhu, Jianhua Feng, Jianfeng Ji, Haifeng Hou, Lin Chen, Shuang Wu, Qing Liu, Qiong Yao, Peizhen Du, Kai Zhang, Qing Chen, Zexin Chen, Hong Zhang, Mei Tian
A landmark study from the Institute of Medicine (IOM) reported that the assessment of cognitive difficulties in children with epilepsy is timely and imperative. Anticonvulsant-induced cognitive impairment could influence the quality of life more than seizure itself in patients. Although monoaminergic system is involved in the regulation of cognitive process, its role in anticonvulsant-induced cognitive impairment remains unclear. Methods: To explore in vivo monoamine receptor binding activity in patients with anticonvulsant-induced cognitive impairment, each patient had PET imaging with both monoamine receptor binding agent, (11)C-N-methylspiperone ((11)C-NMSP), and glucose metabolic agent, (18)F-fluorodeoxyglucose ((18)F-FDG)...
March 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28296213/action-semantic-and-syntactic-deficits-in-subjects-at-risk-for-huntington-s-disease
#11
Adolfo M García, Yamile Bocanegra, Eduar Herrera, Mariana Pino, Edinson Muñoz, Lucas Sedeño, Agustín Ibáñez
Frontostriatal networks play critical roles in grounding action semantics and syntactic skills. Indeed, their atrophy distinctively disrupts both domains, as observed in patients with Huntington's disease (HD) and Parkinson's disease, even during early disease stages. However, frontostriatal degeneration in these conditions may begin up to 15 years before the onset of clinical symptoms, opening avenues for pre-clinical detection via sensitive tasks. Such a mission is particularly critical in HD, given that patients' children have 50% chances of inheriting the disease...
March 11, 2017: Journal of Neuropsychology
https://www.readbyqxmd.com/read/28295799/your-algorithm-might-think-the-hippocampus-grows-in-alzheimer-s-disease-caveats-of-longitudinal-automated-hippocampal-volumetry
#12
Tejas Sankar, Min Tae M Park, Tasha Jawa, Raihaan Patel, Nikhil Bhagwat, Aristotle N Voineskos, Andres M Lozano, M Mallar Chakravarty
Hippocampal atrophy rate-measured using automated techniques applied to structural MRI scans-is considered a sensitive marker of disease progression in Alzheimer's disease, frequently used as an outcome measure in clinical trials. Using publicly accessible data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), we examined 1-year hippocampal atrophy rates generated by each of five automated or semiautomated hippocampal segmentation algorithms in patients with Alzheimer's disease, subjects with mild cognitive impairment, or elderly controls...
March 15, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/28290246/spatio-temporal-fluctuations-of-neural-dynamics-in-mild-cognitive-impairment-and-alzheimer-s-disease
#13
Jesús Poza, Carlos Gómez, María García, Miguel A Tola-Arribas, Alicia Carreres, Mónica Cano, Roberto Hornero
An accurate characterization of neural dynamics in mild cognitive impairment (MCI) is of paramount importance to gain further insights into the underlying neural mechanisms in Alzheimer's disease (AD). Nevertheless, there has been relatively little research on brain dynamics in prodromal AD. As a consequence, its neural substrates remain unclear. In the present research, electroencephalographic (EEG) recordings from patients with dementia due to AD, subjects with MCI due to AD and healthy controls (HC) were analyzed using relative power (RP) in conventional EEG frequency bands and a novel parameter useful to explore the spatio-temporal fluctuations of neural dynamics: the spectral flux (SF)...
March 9, 2017: Current Alzheimer Research
https://www.readbyqxmd.com/read/28290245/differentiated-effective-connectivity-patterns-of-the-executive-control-network-in-progressive-mci-a-potential-biomarker-for-predicting-ad
#14
Suping Cai, Yanlin Peng, Tao Chong, Yun Zhang, Karen M von Deneen, Liyu Huang, Aibl Research Group
Mild cognitive impairment (MCI) is often a transitional state between normal aging and Alzheimer's disease (AD). When observed longitudinally, some MCI patients convert to AD, while a considerable portion either remain MCI or revert to a normal functioning state. This divergence has provided some enlightenment on a potential biomarker be represented in the resting state brain activities of MCI patients with different post-hoc labels. Recent studies have shown impaired executive functions, other than typically explicated memory impairment with AD/MCI patients...
March 9, 2017: Current Alzheimer Research
https://www.readbyqxmd.com/read/28286328/two-distinct-classes-of-degenerative-change-are-independently-linked-to-clinical-progression-in-mild-cognitive-impairment
#15
Jean-Philippe Coutu, Emily R Lindemer, Ender Konukoglu, David H Salat
We previously demonstrated 2 statistically distinct factors of degeneration in Alzheimer's disease: one strongly related to white matter damage and age interpreted as "age- and vascular-related", and the other related to cortical atrophy thought to represent "neurodegenerative changes associated with Alzheimer's disease". Those factors are now replicated in a distinct cross-sectional data set of 364 participants from the Alzheimer's Disease Neuroimaging Initiative and their interpretation is improved using correlations with CSF biomarkers...
February 16, 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28281909/positive-association-of-personal-distress-with-testosterone-in-opiate-addicted-patients
#16
Katrin Stange, Mathias Krüger, Eva Janke, Ralf Lichtinghagen, Stefan Bleich, Thomas Hillemacher, Annemarie Heberlein
BACKGROUND: Clinical studies report that substance addictions are associated with sociocognitive impairments. Regarding opiate addicted patients, the few existing studies point to deficits regarding empathic abilities. Previous research suggests that testosterone might be a relevant biomarker of these impairments. AIMS: We aimed to investigate whether opiate addicted patients show specific impairments in emotional (empathic concern, personal distress) and cognitive empathy compared to healthy controls...
March 10, 2017: Journal of Addictive Diseases
https://www.readbyqxmd.com/read/28281838/diagnostic-function-of-the-neuroinflammatory-biomarker-ykl-40-in-alzheimer-s-disease-and-other-neurodegenerative-diseases
#17
Filippo Baldacci, Simone Lista, Enrica Cavedo, Ubaldo Bonuccelli, Harald Hampel
Neuroinflammation is a fundamental mechanism in the neurodegenerative diseases pathophysiology. Cerebrospinal fluid (CSF) YKL-40 - an indicator of microglial activation - has recently identified by proteomic studies as a candidate biomarker for Alzheimer's disease (AD). Areas covered: We review the impact of CSF YKL-40 as a pathophysiological biomarker for AD and other neurodegenerative diseases. CSF YKL-40 concentrations have been shown to predict progression from prodromal mild cognitive impairment to AD dementia...
March 10, 2017: Expert Review of Proteomics
https://www.readbyqxmd.com/read/28281308/overlapping-but-distinct-tdp-43-and-tau-pathologic-patterns-in-aged-hippocampi
#18
Vanessa D Smith, Adam D Bachstetter, Eseosa Ighodaro, Kelly Roberts, Erin L Abner, David W Fardo, Peter T Nelson
Intracellular proteinaceous aggregates (inclusion bodies) are almost always detectable at autopsy in brains of elderly individuals. Inclusion bodies composed of TDP-43 and tau proteins often coexist in the same brain, and each of these pathologic biomarkers is associated independently with cognitive impairment. However, uncertainties remain about how the presence and neuroanatomical distribution of inclusion bodies correlate with underlying diseases including Alzheimer's disease (AD). To address this knowledge gap, we analyzed data from the University of Kentucky AD Center autopsy series (n = 247); none of the brains had frontotemporal lobar degeneration...
March 9, 2017: Brain Pathology
https://www.readbyqxmd.com/read/28281140/human-predisposition-to-cognitive-impairment-and-its-relation-with-environmental-exposure-to-potentially-toxic-elements
#19
Marina M S Cabral Pinto, A Paula Marinho-Reis, Agostinho Almeida, Carlos M Ordens, Maria M V G Silva, Sandra Freitas, Mário R Simões, Paula I Moreira, Pedro A Dinis, M Luísa Diniz, Eduardo A Ferreira da Silva, M Teresa Condesso de Melo
New lines of evidence suggest that less than 10% of neurodegenerative diseases have a strict genetic aetiology and other factors may be prevalent. Environmental exposures to potentially toxic elements appear to be a risk factor for Parkinson's, Alzheimer's and sclerosis diseases. This study proposes a multidisciplinary approach combining neurosciences, psychology and environmental sciences while integrating socio-economic, neuropsychological, environmental and health data. We present the preliminary results of a neuropsychological assessment carried out in elderly residents of the industrial city of Estarreja...
March 9, 2017: Environmental Geochemistry and Health
https://www.readbyqxmd.com/read/28280223/progressive-disgregation-of-brain-networking-from-normal-aging-to-alzheimer-s-disease-independent-component-analysis-on-fdg-pet-data
#20
Marco Me Pagani, Alessandro Giuliani, Johanna Öberg, Fabrizio De Carli, Silvia Morbelli, Nicola Girtler, Francesca Bongioanni, Dario Arnaldi, Jennifer Accardo, Matteo Bauckneht, Andrea Chincarini, Gianmario Sambuceti, Cathrine Jonsson, Flavio Nobili
Brain connectivity has been assessed in several neurodegenerative disorders investigating the mutual correlations between pre-determined regions or nodes. The selective breakdown of brain networks during the progression from the normal aging (NA) to Alzheimer's Disease (AD) has also been observed. We implemented Independent Component Analysis (ICA) on 18F-FDG-PET data in five groups of subjects with cognitive state ranging from NA to AD dementia, including mild cognitive impairment patients not converting (ncMCI) and converting (MCI) to mild AD dementia, in order to disclose the spatial distribution of the independent components (ICs) in each cognitive state, and their accuracy in discriminating the groups...
March 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
70406
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"